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Nutrition Examination Surveys
Hind A. Beydoun, PhD, MPH1; May A. Beydoun, PhD, MPH2; Hueiwang Anna Jeng, ScD3; Alan B. Zonderman, PhD2; Shaker M. Eid, MD, MBA4
Graduate Program in Public Health, Eastern Virginia Medical School, Norfolk, VA; 2Laboratory of Epidemiology and Population Sciences, National Institute on Aging Intramural
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1

Study Objectives: To evaluate bisphenol-A (BPA) level and its relationship to sleep adequacy in a nationally representative sample of U.S. adults.
Methods: A population-based cross-sectional study was conducted using 2005–2010 National Health and Nutrition Examination Survey whereby data
were collected using in-person interviews, physical examination and laboratory testing. BPA level was measured in urine samples and analyzed as
loge -transformed variable and in quartiles ( < 0.9 ng/mL; 0.9 to < 1.9 ng/mL; 1.9 to < 3.7 ng/mL; 3.7+ ng/mL). Sleep adequacy was operationalized with three
questions: “How much sleep do you usually get at night on weekdays or workdays?”, “Have you ever told a doctor or other health professionals that you
have trouble sleeping?” and “Have you ever been told by a doctor or other health professional that you have a sleep disorder?” Sleep duration was further
categorized as ( < 6 h, ≥ 6 h ); ( < 7 h, 7–8 h, > 8 h ); ( < 5 h, 5–6 h, 7–8 h, ≥ 9 h ). Linear, binary, and ordinal logistic regression models were constructed.
Results: Loge -transformed BPA level was inversely related to sleep duration defined, in hours, as a continuous variable, a dichotomous variable (≥ 6, < 6 ), or
an ordinal variable ( ≥ 9, 7–8, 5–6, < 5 ), after adjustment for confounders. Help-seeking behavior for sleep problems and diagnosis with sleep disorders were
not significantly associated with loge -transformed BPA level in fully adjusted models.
Conclusions: Loge -transformed BPA level may be associated with fewer hours of sleep among U.S. adults, with implications for prevention. Further research
involving diverse populations are needed to confirm these study findings.
Keywords: bisphenol-A, endocrine disruptor, sleep duration, sleep disorder, survey
Citation: Beydoun HA, Beydoun MA, Jeng HA, Zonderman AB, Eid SM. Bisphenol-A and sleep adequacy among adults in the National Health and Nutrition
Examination Surveys. SLEEP 2016;39(2):467–476.
Significance
Among U.S. adults who participated in the 2005–2010 National Health and Nutrition Examination Surveys, an inverse relationship may exist between
urinary loge -transformed bisphenol-A level and sleep duration, but not with diagnosis or treatment for sleep problems.

INTRODUCTION
Growing evidence has implicated sleep as a key player in the
regulation of appetite, metabolic and immune functions.1 In
recent studies, suboptimal sleep duration has been linked to
serious health problems, including obesity, insulin resistance,
type 2 diabetes, hypertension, metabolic syndrome, cardiovascular disease, and cancer.2–41 Sleep disorders, described as difficulty initiating or maintaining sleep or non-restorative sleep,
are highly prevalent and often under-diagnosed in the U.S.42,43
In particular, 10% to 15% of U.S. adults are affected by insomnia.44 Also, 3% to 7% of men and 2% to 5% of women have
diagnoses of obstructive sleep apnea (OSA), whereas 82% of
men and 93% of women with moderate to severe OSA may be
undiagnosed.45
Identification of modifiable risk/protective factors for inadequate sleep is a prerequisite for the design, implementation,
and evaluation of preventive strategies aimed at reducing its
health impact. Whereas dietary habits46,47 and sedentary lifestyle48–54 have recently been correlated with sleep, little research has been done on endocrine disruptors. Bisphenol-A
(BPA) is a carbon-based synthetic compound used in the manufacturing of polycarbonate plastics, epoxy resins, and food and
beverage containers.55–59 It is a ubiquitous endocrine disruptor
with estrogenic activity and is known to exert a wide variety of
metabolic effects leading to reproductive and thyroid hormone
dysregulation, weight gain, glucose intolerance, insulin resistance, type 2 diabetes, metabolic syndrome, cardiovascular
disease, and fatty liver disease.60–69 Recent literature reviews
have pointed out the heterogeneity of epidemiologic evidence
SLEEP, Vol. 39, No. 2, 2016

linking BPA exposure to various health outcomes, rendering
the magnitude of the association difficult to estimate via metaanalyses.70–72 BPA may impact suboptimal sleep and sleep disorders indirectly via its potential role in cardiometabolic risk
factors and health problems.60–69 A direct impact of BPA on the
muscle function in the upper airway leading to OSA has also
been suggested based on analogous findings from biomedical
research.73 Although the link between BPA and sleep appears
to be biologically plausible, to date, only one study has correlated sleep issues with high levels of BPA.73
The aim of this cross-sectional study is to evaluate level
of BPA and its relationship to sleep adequacy (sleep duration, help-seeking behavior for sleep problems, and diagnosis
with sleep disorders) in a nationally representative sample of
U.S. adults, by performing secondary analyses using 2005–
2010 National Health and Nutrition Examination Surveys
(NHANES) data. We hypothesize that BPA level is inversely
related to sleep duration and has a negative impact on sleep
problems and disorders.
METHODS
National Health and Nutrition Examination Surveys 2005–2010
The NHANES is a program of studies conducted by the National Center for Health Statistics, a division of the Centers
for Disease Control and Prevention (CDC), to assess the health
and nutritional status of U.S. children and adults and to determine the prevalence of major diseases and their risk factors.74,75
The NHANES uses stratified multistage cluster sampling with
467
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Covariates
Selected demographic, socioeconomic, lifestyle, and health
characteristics were considered as a priori confounders for
the hypothesized relationships between BPA level and sleep
adequacy, based on the literature.42,43,45,74–83 These include sex
(male, female), age (< 30, 30–39, 40–49, 50–59, 60+ years),
race/ethnicity (Non-Hispanic White, Non-Hispanic Black,
Hispanic, Other), education (less than high school, high school,
more than high school), marital status (married/cohabiting, not
married), poverty income ratio (continuous; < 100%, 100%
to < 200%, ≥ 200%), smoking status (Current smoker, Exsmoker, Never smoker), alcohol consumption (≥ 12 glasses in
the past 12 months) (yes/no), body mass index (BMI) (< 25, 25
to < 30, 30+ kg/m2 ), waist circumference (High: ≥ 102 cm (40
in) in men or ≥ 88 cm (35 in) in women vs. Low: < 102 cm (40
in) in men or < 88 cm (35 in) in women), self-rated health (excellent/very good/good, fair/poor), depressive symptoms based
on the 9-item Patient Health Questionnaire (PHQ) total score
(High: ≥ 10, Low: < 10), and adjusted creatinine level which
was calculated based on equations described by Silver and coworkers.68 Of note, the normal creatinine levels are estimated
to be 0.6 to 1.2 mg/dL in adult males and 0.5 to 1.1 mg/dL in
adult females.

oversampling of African Americans, Asians, Hispanics and
adults 60 years and older.74 Demographic, socioeconomic, and
nutritional data were collected through in-person interviews,
physical examinations and laboratory tests.74,75
Study Participants
Since 1999, NHANES has become a continuous surveillance
system. We selected 31,034 NHANES participants from three
consecutive waves, namely, 2005–2006 (n = 10,348), 2007–
2008 (n = 10,149), and 2009–2010 (n = 10,537).We excluded
pregnant women (n = 507), individuals younger than 20 years
(n = 13,902), and those with missing data on BPA (n = 23,133)
and/or sleep-related questions (n = 11,467). The final sample
consisted of adult non-pregnant 2005–2010 NHANES participants who were 20 years or older, and had no missing data on
key variables of interest (n = 5,034).
Variable Definitions
Bisphenol-A Level

Spot urine samples were obtained from a one-third random
subset of NHANES participants. Total urinary BPA, both
conjugated and free, was analyzed by online solid-phase extraction coupled to high performance liquid chromatography
(HPLC)-isotope dilution tandem mass spectrometry by the
Division of Environmental Health Laboratory Sciences at the
National Center for Environmental Health, CDC.68 The details
of quality assurance and quality control procedures, including
coefficients of variation (CV of 8.1% to 18.6% for the low
BPA quality control pools and 5.7% to 12.1% for the high BPA
quality control pools) and lower limits of detection (LLOD/√2
or 0.28 ng/mL), were described elsewhere.68 After careful examination of its distributional properties, we analyzed BPA
level as a loge -transformed continuous variable and in quartiles (< 0.9 ng/mL; 0.9 to < 1.9 ng/mL; 1.9 to < 3.7 ng/mL; 3.7+
ng/mL). We used quartiles instead of tertiles or quintiles to
maximize our ability to detect a relative risk of ~1.3, assuming
that the proportion having the outcome is 0.1 with α = 0.05 and
β = 0.2.

Statistical Analysis
Statistical analyses were performed using STATA version 12
(STATA Corporation, College Station, TX). Whereas frequencies and percentages were computed for categorical variables,
means and standard errors of the mean (SEM) were computed
for continuous variables. Unadjusted (Model I), age- and sexadjusted (Model II) as well as fully adjusted (Model III) models
were constructed for BPA as a predictor of sleep adequacy,
using ‘svy:reg’ for continuous outcomes, ‘svy:logit’ for binary
outcomes and ‘svy:ologit’ for ordinal outcomes. Measures of
association were presented as beta coefficients with their 95%
confidence intervals (CI) for linear regression models and odds
ratios (OR) with their 95% CI for logistic regression models.
Sampling weights were used to produce correct population
estimates accounting for differential probabilities of selection
and adjusting for non-coverage, non-response, and over-sampling of subpopulations. Two-sided statistical tests were performed at an α level of 0.05.

Sleep Adequacy

Three questions related to sleep adequacy were available
in all 3 waves (2005–2006, 2007–2008, and 2009–2010) of
NHANES data as follows: “How much sleep do you usually
get at night on weekdays or workdays?” (Q1: Sleep duration),
“Have you ever told a doctor or other health professionals that
you have trouble sleeping?”(Q2: Help-seeking behavior for
sleep problems) and “Have you ever been told by a doctor or
other health professional that you have a sleep disorder?” (Q3:
Diagnosis with sleep disorders). Responses to Q1 were measured on a continuous scale as number of hours, and responses
to Q2 and Q3 were dichotomous “yes” or “no”76; Q1 was also
analyzed as a categorical variable using 3 distinct definitions
based on recent studies of NHANES data, namely: definition 1
(“short sleep (yes): < 6 h,” “short sleep (no): ≥ 6 h”);43 definition
2 (“short sleep: < 7 h,” “normal sleep: 7–8 h,” “long sleep: > 8
h”);76 definition 3 (“very short sleep: < 5 h,” “short sleep: 5–6
h,” “normal sleep: 7–8 h,” “long sleep: ≥ 9 h”).77
SLEEP, Vol. 39, No. 2, 2016

RESULTS
Between 2005 and 2010, 5,034 participants met inclusion criteria in this study; 2,564 were men and 2,470 were women.
Table 1 details the demographic, socioeconomic, lifestyle,
and health characteristics of the study participants by sex.
Overall, the mean (± SEM) for age, BMI, waist circumference,
depressive symptoms, and adjusted creatinine level were
47.0 ± 0.35 years, 28.7 ± 0.1 kg/m 2, 97.9 ± 0.4 cm, 2.8 ± 0.08,
and 909614.2 ± 13896.9 mg/dL, respectively. Furthermore,
24% were ≥ 60 years, 70% were non-Hispanic White, 57%
had more than high school education, 58% were married, 63%
had poverty income ratio > 2, 53% never smoked, and 76%
drank alcohol in the past 12 months. Also, 35% had BMI ≥ 30
kg/m 2, 52% had a high waist circumference, 84% had excellent, very good, or good self-rated health, and 6% had high
468
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Table 1—Demographic, socioeconomic, lifestyle and health characteristics of study sample by sex: National Health and Nutrition Examination Surveys
2005–2010 (n = 5,034).
Total (n = 5,034)
n = 5,034
47.0 ± 0.35

Males (n = 2,564)
n = 2,564
45.9 ± 0.5

Females (n = 2,470)
n = 2,470
48.1 ± 0.4

18.2
18.2
21.1
18.7
23.8

19.9
18.9
20.9
18.6
21.6

16.6
17.4
21.3
18.8
25.9

Race
White
Black
Hispanic
Other

n = 5,034
70.5
11.3
12.4
5.8

n = 2,564
70.3
10.5
13.5
5.7

n = 2,470
70.7
12.1
11.4
5.9

0.1

Education
Less than high school
High school
More than high school

n = 5,028
18.4
24.9
56.6

n = 2,562
19.0
24.3
56.7

n = 2,466
17.9
25.5
56.6

0.5

Marital status
Married
Not married

n = 5,030
58.3
41.7

n = 2,562
61.9
38.1

n = 2,468
54.7
45.3

0.0001

Poverty income ratio
<1
1–2
≥2

n = 5,025
18.5
18.9
62.6

n = 2,561
16.6
18.1
65.2

n = 2,464
20.3
19.7
60.0

0.0007

Smoking status
Current smoker
Ex-smoker
Never smoker

n = 5,030
22.8
24.8
52.5

n = 2,562
24.9
28.0
47.1

n = 2,468
20.7
21.6
57.7

< 0.0001

Alcohol (past 12 months)
Yes
No

n = 4,608
76.0
23.9

n = 2,365
85.6
14.4

n = 2,243
66.5
33.5

< 0.0001

Body mass index (kg/m2)
Mean ± SEM
Categorical
< 25
25–30
≥ 30

n = 4,987
28.7 ± 0.1

n = 2,534
28.8 ± 0.2

n = 2,453
28.5 ± 0.2

32.0
32.9
34.9

26.6
38.4
34.9

37.2
27.8
34.9

Waist circumference (cm)*
Mean ± SEM
Categorical
High
Low

n = 5,034
97.9 ± 0.4

n = 2,564
101.4 ± 0.5

n = 2,470
94.7 ± 0.4

51.8
48.2

43.3
56.7

60.0
39.9

Self-rated health
Excellent/Very good/Good
Fair/Poor

n = 4,622
83.5
16.5

n = 2,373
83.8
16.2

n = 2,249
83.1
16.9

Depressive symptoms
Mean ± SEM
Categorical
High (≥ 10)
Low (< 10)

n = 5,034
2.8 ± 0.08

n = 2,564
2.3 ± 0.08

n = 2,470
3.2 ± 0.1

5.9
94.1

4.4
95.6

7.3
92.7

n = 5,034
909614.2 ± 13896.9

n = 2,564
1092170 ± 18177.8

n = 2,470
731908.2 ± 18516.82

Age (years)
Mean ± SEM
Categorical
< 30
30–39
40–49
50–59
≥ 60

Creatinine (mg/dL) – adjusted
Mean ± SEM

P value
0.001
0.03

0.2
< 0.0001

< 0.0001
< 0.0001

0.6

< 0.0001
0.0001

< 0.0001

*“High” refers to waist circumference > 102 cm in males and > 88 cm in females.
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Table 2—Urinary bisphenol level and sleep adequacy of study sample by sex: National Health and Nutrition Examination Surveys 2005–2010
(n = 5,034).
Total (n = 5,034)
n = 5,034
4.2 ± 0.4

Males (n = 2,564)
n = 2,564
4.4 ± 0.5

Females (n = 2,470)
n = 2,470
4.0 ± 0.4

23.3
26.1
25.9
24.7

19.4
27.0
28.3
25.3

27.1
25.2
23.6
24.2

Sleep duration
Mean ± SEM
Categorical 1
<6
≥6
Categorical 2
<7
7–8
>8
Categorical 3
<5
5–6
7–8
≥9

n = 5,023
6.9 ± 0.03
n = 5,023
12.8
87.2
n = 5,023
37.9
55.3
6.8
n = 5,023
4.6
33.3
55.3
6.8

n = 2,560
6.8 ± 0.03
n = 2,560
13.8
86.2
n = 2,560
39.3
55.3
5.4
n = 2,560
4.7
34.6
55.3
5.4

n = 2,463
6.9 ± 0.03
n = 2,463
11.8
88.2
n = 2,463
36.6
55.3
8.1
n = 2,463
4.4
32.2
55.3
8.1

Ever told doctor had trouble sleeping
Yes
No

n = 5,029
24.2
75.8

n = 2,561
19.9
80.1

n = 2,468
28.3
71.7

< 0.0001

Ever told by doctor had sleeping disorder
Yes
No

n = 5,026
7.7
92.3

n = 2,558
8.8
91.2

n = 2,468
6.6
93.4

0.03

Bisphenol-A (ng/ml)
Mean ± SEM
Quartiles
< 0.9
0.9–1.9
1.9–3.7
≥ 3.7

†

P value
< 0.0001 †
0.0001

0.002
0.11
0.001

0.004

Log-transformed values were compared according to sex.

depressive symptoms. All these characteristics differed
significantly by sex, with the exception of race, education, and
self-rated health.
BPA levels and sleep adequacy of the study participants
by sex are presented in Table 2. Overall, the mean (± SEM)
for BPA level and duration of sleep were 4.2 ± 0.4 ng/mL
and 6.9 ± 0.03 h, respectively. Furthermore, 87% reported
sleeping ≥ 6 h, 55% 7 to 8 h, and 7% ≥ 9 h. Moreover, 24%
reported ever telling a doctor that they had trouble sleeping,
and only 8% were ever diagnosed with a sleep disorder. All
these characteristics were significantly different among men
and women, with the exception of the binary definition (< 6 h
vs. ≥ 6 h) of sleep duration.
Table 3 presents urinary BPA level as a predictor of sleep
duration defined as a continuous or categorical variable in
unadjusted (Model I), sex- and age-adjusted (Model II), and
fully adjusted (Model III) models. As expected, an inverse
relationship was observed between sleep duration, defined as
a continuous variable, and loge -transformed BPA level in all
three models (Model I: −0.06 [−0.09, −0.02]; Model II: −0.06
[−0.09, −0.02]; Model III: −0.05 [−0.09, −0.002]). Taking the
lowest quartile as a referent group, the upper quartile of BPA
was inversely related to sleep duration, defined as a continuous
variable, in the unadjusted (β = −0.2, 95% CI: −0.3, −0.03) as
well as sex- and age-adjusted model (β = −0.2, 95% CI: −0.3,
SLEEP, Vol. 39, No. 2, 2016

−0.03), but not the fully adjusted model (β = −0.12, 95% CI:
−0.3, 0.02). The categorical definitions 1 (short sleep (yes): < 6
h, short sleep (no): ≥ 6 h) and 3 (very short sleep: < 5 h, short
sleep: 5–6 h, normal sleep: 7–8 h, long sleep: ≥ 9 h) for sleep
duration were inversely and significantly related to loge -transformed BPA level in unadjusted, sex- and age-adjusted and
fully adjusted models. By contrast, the categorical definition
2 (short sleep: < 7 h, normal sleep: 7–8 h, long sleep: > 8 h) for
sleep duration was inversely and significantly related to loge transformed BPA level only in the unadjusted and sex- and
age-adjusted models. When defined as quartiles, BPA level
was inversely and significantly related to categorical definition
1 of sleep duration in the unadjusted model as well as categorical definitions 2 and 3 of sleep duration in the unadjusted and
sex- and age-adjusted models.
Table 4 presents urinary BPA level as a predictor of selfreported sleep problems in unadjusted, sex- and age-adjusted
and fully adjusted models. Clearly, only unadjusted models
yielded significant and positive relationships between having
told a doctor that he/she had trouble sleeping and urinary BPA
level defined either as a continuous variable (OR = 1.08, 95%
CI: 1.01, 1.16) or in quartiles (Q4 vs. Q1: OR = 1.24, 95% CI:
1.01, 1.52). By contrast, no significant relationship was observed between urinary BPA level and ever being told by a
doctor that he/she had a sleeping disorder in the 3 models.
470
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Table 3—Urinary bisphenol level as a predictor of sleep duration defined as a continuous or categorical variable.
Sleep duration (hours) – Continuous
Urinary bisphenol level (ng/mL) – Continuous
Urinary bisphenol level (ng/mL) – Quartiles
< 0.9
0.9–1.9
1.9–3.7
≥ 3.7
Hours of sleep – Categorical 1
Urinary bisphenol level (ng/mL) – Continuous
Urinary bisphenol level (ng/mL) – Quartiles
< 0.9
0.9–1.9
1.9–3.7
≥ 3.7

Model I: Unadjusted
β (95% CI)
−0.06 (−0.09, −0.02)
P = 0.007
Ref.
−0.05 (−0.18, 0.08)
−0.1 (−0.3, −0.01)
−0.2 (−0.3, −0.03)
OR (95% CI)
0.87 (0.79, 0.94)
P = 0.02
Ref.
1.03 (0.78, 1.36)
0.77 (0.57, 1.04)
0.73 (0.53, 0.99)

Model II: Age-and-Sex Adjusted
β (95% CI)
−0.06 (−0.09, −0.02)
P = 0.006
Ref.
−0.05 (−0.18, 0.09)
−0.1 (−0.2, 0.008)
−0.2 (−0.3, −0.03)
OR (95% CI)
0.87 (0.79, 0.95)
P = 0.03
Ref.
1.04 (0.79, 1.38)
0.79 (0.58, 1.08)
0.73 (0.52, 1.02)

Model III: Fully Adjusted
β (95% CI)
−0.05 (−0.09, −0.002)
P = 0.1
Ref.
−0.08 (−0.2, 0.06)
−0.09 (−0.2, 0.04)
−0.12 (−0.3, 0.02)
OR (95% CI)
0.88 (0.79, 0.98)
P = 0.1
Ref.
0.94 (0.70, 1.26)
0.79 (0.57, 1.11)
0.76 (0.52, 1.11)

Sleep duration (hours) – Categorical 2
Urinary bisphenol level (ng/mL) – Continuous
Urinary bisphenol level (ng/mL) – Quartiles
< 0.9
0.9–1.9
1.9–3.7
≥ 3.7
Sleep duration (h) – Categorical 3
Urinary bisphenol level (ng/mL) – Continuous
Urinary bisphenol level (ng/mL) – Quartiles
< 0.9
0.9–1.9
1.9–3.7
≥ 3.7

Model I: Unadjusted
OR (95% CI)
0.93 (0.88, 0.98)
P < 0.0001
Ref.
0.88 (0.69, 1.12)
0.91 (0.73, 1.13)
0.77 (0.63, 0.93)
OR (95% CI)
0.81 (0.70, 0.93)
P = 0.03
Ref.
0.98 (0.57, 1.69)
0.71 (0.42, 1.19)
0.62 (0.39, 0.99)

Model II: Age-and-Sex Adjusted
OR (95% CI)
0.93 (0.88, 0.98)
P = 0.02
Ref.
0.88 (0.69, 1.12)
0.91 (0.73, 1.14)
0.77 (0.63, 0.93)
OR (95% CI)
0.78 (0.67, 0.91)
P = 0.02
Ref.
0.94 (0.55, 1.62)
0.65 (0.38, 1.13)
0.56 (0.34, 0.93)

Model III: Fully Adjusted*
OR (95% CI)
0.97 (0.91, 1.03)
P = 0.44
Ref.
0.85 (0.65, 1.12)
0.99 (0.75, 1.32)
0.86 (0.68, 1.08)
OR (95% CI)
0.79 (0.67, 0.94)
P = 0.06
Ref.
0.92 (0.49, 1.75)
0.69 (0.39, 1.22)
0.63 (0.35, 1.12)

*Adjusted for sex (male, female), age (< 30, 30–39, 40–49, 50–59, ≥ 60 years), race/ethnicity (Non-Hispanic White, Non-Hispanic Black, Hispanic,
Other), education (less than high school, high school, more than high school), marital status (married/cohabiting, not married), poverty income ratio
(continuous; < 100%, 100%–200%, ≥ 200%), smoking status (current smoker, ex-smoker, never smoker), alcohol consumption (at least 12 glasses in the
past 12 months) (yes, no), body mass index (BMI) (< 25, 25–30, ≥ 30 kg/m2), waist circumference (High: ≥ 102 cm (40 in) in men or ≥ 88 cm (35 in) in women
vs. Low: < 102 cm (40 in) in men or < 88 cm (35 in) in women), self-rated health (excellent/very good/good, fair/poor), depressive symptoms based on the
9-item Patient Health Questionnaire (PHQ) total score (high: ≥ 10, low: < 10) and adjusted creatinine level.

DISCUSSION
In this cross-sectional study, we investigated whether BPA was
associated with sleep adequacy in a nationally representative
sample of U.S. adults in whom self-reported sleep duration,
help-seeking behavior for sleep problems, and diagnosis with
sleep disorders were considered as the main outcomes of interest. Consistent with our hypotheses, the results indicated
that loge -transformed BPA level was inversely related to sleep
duration defined, in hours as a continuous variable, a dichotomous variable (≥ 6 vs. < 6) or an ordinal variable (≥ 9, 7–8,
5–6, < 5), after adjustment for confounders. By contrast, helpseeking behavior for sleep problems and diagnosis with sleep
disorders were not significantly associated with loge -transformed BPA level in the fully adjusted models. Also, when
BPA level was defined in quartiles, its relationship with sleep
adequacy did not reach statistical significance after controlling
SLEEP, Vol. 39, No. 2, 2016

for demographic, lifestyle, and health characteristics of the
study sample. The latter finding suggests a complex nonlinear
relationship between BPA and indicators of sleep adequacy.
Emerging evidence suggests that BPA, atrazine, dichlorodiphenyltrichloroethane, diethylstilbestrol, dioxin, phthalates,
polychlorinated biphenyls, organotins, and other endocrine
disruptors may have negative health effects.84–91 Endocrine disruptors are lipophilic substances that usually act as transcription factors for nuclear hormone receptor superfamily and can
either mimic or block the action of endogenous sex hormones,
resulting in irreversible alterations or reversible alterations in
patterns of gene expression.84,86–91 Sex steroids (androgens and
estrogens) play an important role in establishing and maintaining adipose tissue84,85 and in conjunction with growth hormones can mobilize lipids and have anti-adipogenic effects;
their effects are counteracted by insulin and cortisol that have
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Table 4—Urinary bisphenol level as a predictor of self-reported sleep problems.
Ever told doctor had trouble sleeping
Urinary bisphenol level (ng/mL) – Continuous
Urinary bisphenol level (ng/mL) – Quartiles
< 0.9
0.9–1.9
1.9–3.7
≥ 3.7
Ever told by doctor had sleeping disorder
Urinary bisphenol level (ng/mL) – Continuous
Urinary bisphenol level (ng/mL) – Quartiles
< 0.9
0.9–1.9
1.9–3.7
≥ 3.7

Model I: Unadjusted
OR (95% CI)
1.08 (1.01, 1.16)
P = 0.1
Ref.
1.19 (0.94, 1.52)
1.11 (0.88, 1.39)
1.24 (1.01, 1.52)
OR (95% CI)
1.02 (0.89, 1.16)
P = 0.9
Ref.
1.01 (0.66, 1.54)
0.85 (0.56, 1.28)
1.09 (0.72, 1.67)

Model II: Age-and-Sex Adjusted
OR (95% CI)
1.03 (0.96, 1.11)
P = 0.9
Ref.
1.08 (0.85, 1.39)
0.96 (0.75, 1.22)
1.06 (0.85, 1.34)
OR (95% CI)
0.98 (0.86, 1.12)
P = 0.6
Ref.
0.98 (0.63, 1.52)
0.79 (0.51, 1.22)
0.97 (0.62, 1.52)

Model III: Fully Adjusted*
OR (95% CI)
1.08 (0.99, 1.19)
P = 0.4
Ref.
1.13 (0.86, 1.49)
1.03 (0.77, 1.39)
1.19 (0.89, 1.59)
OR (95% CI)
1.05 (0.89, 1.24)
P = 0.8
Ref.
1.18 (0.74, 1.88)
0.95 (0.58, 1.57)
1.18 (0.71, 1.98)

*Adjusted for sex (male, female), age (< 30, 30–39, 40–49, 50–59, ≥ 60 years), race/ethnicity (Non-Hispanic White, Non-Hispanic Black, Hispanic,
Other), education (less than high school, high school, more than high school), marital status (married/cohabiting, not married), poverty income ratio
(continuous; < 100%, 100%–200%, ≥ 200%), smoking status (current smoker, ex-smoker, never smoker), alcohol consumption (at least 12 glasses in the
past 12 months) (yes, no), body mass index (BMI) (< 25, 25–30, ≥ 30 kg/m2 ), waist circumference (high: ≥ 102 cm (40 in) in men or ≥ 88 cm (35 in) in women
vs. low: < 102 cm (40 in) in men or < 88 cm (35 in) in women), self-rated health (excellent/very good/good, fair/poor), depressive symptoms based on the
9-item Patient Health Questionnaire (PHQ) total score (high: ≥ 10, low: < 10) and adjusted creatinine level.

syndrome, in the observed relationship between BPA and sleep
duration. While the proposed biological mechanisms are plausible, reverse causality cannot be ruled out as a potential explanation for the observed associations. In fact, it is also plausible
that individuals who experience shorter sleep are more likely
to experience environmental BPA exposure which, in turn, assumes a state of wakefulness.
To our knowledge, this is the first study examining whether
BPA may be causally or non-causally linked to adequacy of
sleep in a nationally representative sample of U.S. adults. Previous studies have used NHANES data to examine correlates
of sleep, including race/ethnicity,43,83 socioeconomic status,83
eating behaviors,80 nutritional biomarkers,77,79 alcohol use,74
obesity,76 pre-diabetes,78 diabetes,76 hypertension,82 homocysteine,45 inflammatory biomarkers,43,81 cardiovascular disease,42
anxiety,75 and functional health.43 In a recent study, Erden and
colleagues41 evaluated the associations among OSA, BPA, vitamin D, and parathyroid hormone levels using a sample of
128 subjects who had undergone polysomnography and were
classified as control (n = 43), moderate OSA (n = 23), or severe OSA (n = 62).41 Consistent with our findings, their results
indicated that while vitamin D level was lower in both OSA
groups and PTH was higher in OSA groups than in the control
subjects, and BPA levels were higher in severe OSA than moderate OSA and controls.41
Nevertheless, our findings should be interpreted with caution and in light of several limitations. First, the study design is
cross-sectional, which precludes establishing cause-and-effect
relationships among variables under study. Second, analyses
were based on previously collected data reducing flexibility in
the definition of outcome, exposure, and covariate variables.
Third, BPA metabolites were assessed by a single assay in

adipogenic effects.84 Exposure to endocrine disruptors such
as BPA is thought to promote adiposity typical of Cushing
syndrome, polycystic ovary syndrome, growth hormone deficiency, menopause, aging, alcoholism, and depression.84,88
Since the 1960s, BPA has been produced in large quantities
for the manufacturing of flame retardants, dental sealants and
fillings, adhesives, protective coatings, infant feeding bottles,
food and mineral water storage containers, and food and beverage can linings.84,92–98 Although studies have suggested that
low-dose BPA exposure may be associated with increased
reproductive and cancer risks,99–105 regulatory bodies in the
U.S., Canada, and Europe have distinct views on whether BPA
should be considered a hazardous substance.106
So far, a limited number of studies have used a nationally
representative sample to investigate health effects of BPA, and
several of these studies, most of which used NHANES data,
have linked high BPA to obesity-related cardiometabolic risk
factors and conditions.69,92,93,107–109 The finding of an inverse relationship between sleep duration and BPA level is consistent
with the current evidence that BPA is a chemical substance
that has the capacity to bind nuclear and membrane surface
estrogen receptors, resulting in obesity-related disturbances
which can potentially mediate suboptimal sleep.58,59,64,66,69
However, our results also suggest that BPA level may be negatively associated with sleep duration, independently of BMI
or waist circumference, both of which are indices of obesityrelated disturbances. Therefore, it is also plausible that BPA
may have an adverse impact on muscular function in the upper
airway, causing sleep disorders such as OSA, as suggested by
biomedical researchers.41 In-depth analyses are needed to evaluate the mediating role of obesity-related cardiometabolic risk
factors and conditions, including components of the metabolic
SLEEP, Vol. 39, No. 2, 2016
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NHANES, which may not represent diurnal changes in BPA
levels. Fourth, the study sample was selected on the basis of
availability of exposure and outcome data, which may have
resulted in selection bias. In particular, the inclusion and exclusion criteria that define the selected subset of NHANES
2005–2010 subjects may have influenced the effectiveness of
weighting variables. Further analyses suggested that the selected and non-selected adult subjects differed significantly
on sex, age, race/ethnicity, and education. Fifth, NHANES
assessed adequacy of sleep using self-report rather than polysomnography or medical records data, which may have led to
non-differential misclassification of the outcome variables of
interest, potentially biasing measures of association towards
the null value. Moreover, the question pertaining to sleep duration was limited in scope as it only considered week or workdays. Considering the existence of sleep compensation (short
sleep during week or workdays and longer sleep on weekends
or free days), the general sleep time is underestimated. Also,
at least one of the sleep-related outcomes is a rare event with a
prevalence of less than 10%, reducing our ability to detect an
association with BPA exposure.
Sixth, although numerous covariates were included in the
multivariable models, we cannot rule out residual confounding
as an explanation for the observed associations due to uncontrolled factors such as area of residence and diet quality.
Seventh, although sex differences were observed, we could
not conduct stratified analyses according to sex as a result of
sample size limitations. Finally, our findings can only be generalized to adult men and women, and further research is needed
to evaluate these relationships in adolescents and children.
In conclusion, secondary analyses of 2005–2010 NHANES
data involving U.S. adults suggests that sleep duration, but not
help-seeking behaviors related to poor sleep, may be inversely
related to BPA level, with implications for primary and secondary prevention. Regulation of environmental BPA level
could potentially reduce the risk of adverse health outcomes,
including poor sleep. Also, monitoring of BPA level by healthcare professionals could help identify patients at high risk for
poor sleep and aid in the management of patients experiencing
poor sleep. Our results support the idea that excessively high
levels of BPA may, directly or indirectly, be linked to poor
sleep. Further research is needed to better understand what
specific environmental exposures may have led to excessive
levels of BPA and consequently adverse outcomes such as inadequate sleep.

PHQ, Patient Health Questionnaire
SEM, standard error of the mean
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